Back to Journals » Hepatic Medicine: Evidence and Research » Volume 7

Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients

Authors Bertrand J, Caillol F, Borentain P, Raoul J, Heyries L, Bories E, Pesenti C, Ratone J, Bernard J, Gerolami R, Giovannini M

Received 19 May 2014

Accepted for publication 5 January 2015

Published 19 May 2015 Volume 2015:7 Pages 21—27


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Gerry Lake-Bakaar

Julie Bertrand,1 Fabrice Caillol,1 Patrick Borentain,2 Jean-Luc Raoul,1 Laurent Heyries,2 Erwan Bories,1 Christian Pesenti,1 Jean-Philippe Ratone,2 Jean-Paul Bernard,2 René Gerolami,2 Marc Giovannini1

1Endoscopy Unit, Paoli Calmettes Institute, Marseille, France; 2Department of Hepato-Gastroenterology, Conception Hospital, Marseille, France

Abstract: Radiofrequency ablation (RFA) is a curative option for hepatocellular carcinoma (HCC), the most common primary malignancy of the liver. This bicentric retrospective study includes 46 patients admitted for their first percutaneous RFA for HCC. Sixty-three nodules were treated, with an average size of 32.5 mm. Our study confirms the efficiency of this technique for attaining necrosis of HCC nodules, with few complications. Subgroup studies according to RFA mode (mono- or multipolar), etiology of cirrhosis (alcoholic or viral), and HCC size showed better efficiency for multipolar RFA when applied to small tumors and better survival when the cirrhosis was due to viral infection. However, we noted a high rate of local recurrence in our and other recent works compared to previous studies, probably due to improved imaging techniques. The main problem is still de novo intrahepatic recurrence in diseased livers.

Keywords: radiofrequency ablation, cirrhosis, HCC

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]